BIOTRONIK Blog

Explore our latest insightful interviews and articles

Patient reading on the iPad

Blog Stories

Filter and Search

51 blog articles
Blog

Mindfulness Isn’t Just a Buzzword at BIOTRONIK

With 2023 upon us, BIOTRONIK employees are no exception to the kind of motivated goal-setting we often see at this time of year. Whether it’s more sports, a more mindful approach to everyday life, or to quit smoking—it’s important to have as much support as possible. That’s why BIOTRONIK’s Health Program 2023 will work to empower employees to achieve their health-related goals. 2023’s edition places a special focus on improving mental health at work, alongside the company’s work to promote physical health.
Blog

Myth or Fact? Your Device Security Questions Answered

While in office as US Vice-President, Dick Cheney had the remote monitoring function of his pacemaker turned off over concerns a malicious hacker could access his device. In 2012, an episode of the TV drama Homeland depicts a faraway terrorist hacking into the fictional US Vice-President’s pacemaker and assassinating him. It may have made for thrilling TV, but is successful malicious hacking of a cardiac device possible in real life?

Subscribe for our News

I prefer to be contacted by
*Fields are mandatory.

Latest Press Releases

Show all press releases
BERLIN, Germany
BIOTRONIK Driving the Future of Active Device Business

BIOTRONIK Driving the Future of Active Device Business

BIOTRONIK, a global leader in medical technology, and a pioneer in cardiovascular, endovascular, and neuromodulation solutions, today announced a strategic shift to strengthen its leadership in active implantable devices and digital healthcare. Leveraging future technologies, including artificial intelligence (AI), remote patient monitoring and connected healthcare platforms, BIOTRONIK is at the forefront of improving patient outcomes and optimizing clinical workflows. These innovations are designed to enhance the efficiency and accessibility of care, enabling healthcare providers with next
BUELACH, Switzerland
Press Release

BIOTRONIK Begins BIOMAG-LL Pre-Market Trial to Evaluate Freesolve® Resorbable Magnesium Scaffold for Treatment of Long Lesions

BIOTRONIK, a global leader in cardiovascular, endovascular, and neuromodulation solutions, today announces the launch of BIOMAG-LL, a pre-market trial focused on confirming the safety and clinical performance of Freesolve ® Resorbable Magnesium Scaffold (RMS), for the treatment of long de novo lesions in native coronary arteries. The BIOMAG-LL is a prospective, international, multi-center, single arm pre-market study that will enroll 100 patients in Europe with de novo coronary artery stenosis and long lesions. Given that the Freesolve RMS is already CE-certified for shorter lesions, the
Prospera SCS
ORLANDO, Florida, USA
Press Release

New Data Show Significant Pain Relief, Reduced Opioid Use, Decreased Patient Time and Cost Burdens with the ProsperaTM SCS System

BIOTRONIK Neuro will unveil new data from the BENEFIT-03 clinical study at the North American Neuromodulation Society (NANS) 2025 Annual Meeting. The findings highlight the transformative potential of its Prospera TM Spinal Cord Stimulation (SCS) system. This system integrates RESONANCE™ multiphase stimulation with automatic, objective, daily remote monitoring and proactive care* to optimize management of SCS patients’ chronic pain. 1 The 24-month data revealed that participants experienced significant pain relief, along with better sleep, improved function and reduced opioid medication use

Press Contact